TY - JOUR
T1 - The relationships between cancer and autoimmune rheumatic diseases
AU - Cappelli, Laura C.
AU - Shah, Ami A.
N1 - Funding Information:
LCC has received research funding from Bristol-Myers Squibb and has been a consultant for Regeneron/Sanofi. AAS has been a consultant for Bristol-Myers Squibb.
Funding Information:
LCC has received research funding from Bristol-Myers Squibb and has been a consultant for Regeneron/Sanofi. AAS has been a consultant for Bristol-Myers Squibb.LCC was supported by NIH/NIAMS K23-AR075872 and an investigator initiated grant from Bristol-Myers Squibb. AAS was supported by NIH/NIAMS R01- AR073208. Both authors were supported by NIH/NIAMS P30-AR070254. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
LCC was supported by NIH/NIAMS K23-AR075872 and an investigator initiated grant from Bristol-Myers Squibb . AAS was supported by NIH/NIAMS R01- AR073208 . Both authors were supported by NIH/ NIAMS P30-AR070254 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2020/2
Y1 - 2020/2
N2 - Links between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that targeted cancer screening strategies can be considered. Multiple mechanisms linking autoimmune rheumatic diseases and cancer are discussed, including the development of autoimmunity in the context of naturally occurring anti-tumor immune responses and malignancy arising in the context of inflammation and damage from autoimmunity. Immunosuppression for rheumatic disease can increase risk for certain types of cancers. Finally, immune checkpoint inhibitors, a type of cancer immunotherapy, which cause a variety of inflammatory syndromes of importance to rheumatologists, are reviewed.
AB - Links between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that targeted cancer screening strategies can be considered. Multiple mechanisms linking autoimmune rheumatic diseases and cancer are discussed, including the development of autoimmunity in the context of naturally occurring anti-tumor immune responses and malignancy arising in the context of inflammation and damage from autoimmunity. Immunosuppression for rheumatic disease can increase risk for certain types of cancers. Finally, immune checkpoint inhibitors, a type of cancer immunotherapy, which cause a variety of inflammatory syndromes of importance to rheumatologists, are reviewed.
KW - Autoantibodies
KW - Autoimmunity
KW - Cancer
KW - Immune checkpoint inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85078857076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078857076&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2019.101472
DO - 10.1016/j.berh.2019.101472
M3 - Review article
C2 - 32029389
AN - SCOPUS:85078857076
SN - 1521-6942
VL - 34
JO - Best Practice and Research: Clinical Rheumatology
JF - Best Practice and Research: Clinical Rheumatology
IS - 1
M1 - 101472
ER -